AR044851A1 - Compuestos heterociclicos, antagonistas del receptor m3 muscarinico - Google Patents

Compuestos heterociclicos, antagonistas del receptor m3 muscarinico

Info

Publication number
AR044851A1
AR044851A1 ARP040102162A ARP040102162A AR044851A1 AR 044851 A1 AR044851 A1 AR 044851A1 AR P040102162 A ARP040102162 A AR P040102162A AR P040102162 A ARP040102162 A AR P040102162A AR 044851 A1 AR044851 A1 AR 044851A1
Authority
AR
Argentina
Prior art keywords
compounds
alkyl
atoms
membered heterocyclic
ring atom
Prior art date
Application number
ARP040102162A
Other languages
English (en)
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=33554160&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR044851(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB0314697A external-priority patent/GB0314697D0/en
Priority claimed from GB0327526A external-priority patent/GB0327526D0/en
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of AR044851A1 publication Critical patent/AR044851A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Los compuestos de la presente son útiles para tratar condiciones que están mediadas por el receptor M3 muscarínico. También se describen las composiciones, farmacéuticas que contienen los compuestos y un procedimiento para preparar los compuestos. Reivindicación 1: Un compuesto de la fórmula (1) en forma de sal o zwiteriónica en donde: R1 y R3 son cada uno independientemente un grupo carbocíclico de 3 a 15 átomos de C o un grupo heterocíclico de 5 a 12 miembros que tiene por lo menos un átomo heterogéneo de anillo seleccionado de N, O y S; R2 es H, hidroxi, o alquilo C1-4 opcionalmente sustituido por hidroxi; L y M son (un enlace y -CH2-CH2-), (-CH2- y -CH2-CH2-) o (-CH2-CH2- y -CH2-) respectivamente y J es alquileno C1-2, o L y M son (-CH2- y -CH2-CH2-) o (-CH2-CH2- y -CH2-) respectivamente y J es un enlace; R4 es alquilo C1-4; R5 es alquilo de 1 átomo de carbono sustituido por -SO-R6, -S(=O)2, -CO-R6, -CO-O-R6, -CO-NH-R6 o -R7, o R5 es alquilo C2-10 sustituido -O-R6, -S-R6, -SO-R6, S(=O)2-R6, -CO-R6, -O-CO-R6, -CO-O-R6, -NH-CO-R6, -CO-NH-R6, -R7 o -R8. o R5 es alquenilo C2-10 o alquinilo C2-10 opcionalmente sustituido por -R7 o -R8; R6 es un grupo carbocíclico de 3 a 15 átomos de C o un grupo heterocíclico de5 a 12 miembros que tiene por lo menos un átomo heterogéneo de anillo seleccionado de N, O o S; o R6 es alquilo C1-10 opcionalmente sustituido por alcoxi C1-10, -O-R7, un grupo carbocíclico de 3 a 15 átomos de C o un grupo heterocíclico de 5 a 12 miembros que tiene por lo menos un átomo heterogéneo de anillo seleccionado de N, O o S; R7 es un grupo heterocíclico de 5 a 12 miembros que tiene por lo menos un átomo heterogéneo de anillo seleccionado de N, O o S, y R8 es un grupo carbocíclico de 3 a 15 átomos de C.
ARP040102162A 2003-06-24 2004-06-22 Compuestos heterociclicos, antagonistas del receptor m3 muscarinico AR044851A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0314697A GB0314697D0 (en) 2003-06-24 2003-06-24 Organic compounds
GB0327526A GB0327526D0 (en) 2003-11-26 2003-11-26 Organic compounds

Publications (1)

Publication Number Publication Date
AR044851A1 true AR044851A1 (es) 2005-10-05

Family

ID=33554160

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP040102162A AR044851A1 (es) 2003-06-24 2004-06-22 Compuestos heterociclicos, antagonistas del receptor m3 muscarinico

Country Status (15)

Country Link
US (1) US7947730B2 (es)
EP (1) EP1638940B1 (es)
JP (1) JP2008529965A (es)
AR (1) AR044851A1 (es)
AT (1) ATE478845T1 (es)
AU (1) AU2004251867B2 (es)
BR (1) BRPI0411738A (es)
CA (1) CA2526991C (es)
DE (1) DE602004028821D1 (es)
MX (1) MXPA05013823A (es)
PE (1) PE20050231A1 (es)
PL (1) PL1638940T3 (es)
PT (1) PT1638940E (es)
TW (1) TW200526573A (es)
WO (1) WO2005000815A2 (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0410712D0 (en) 2004-05-13 2004-06-16 Novartis Ag Organic compounds
GB0428416D0 (en) * 2004-12-24 2005-02-02 Novartis Ag Organic compounds
GB0428418D0 (en) * 2004-12-24 2005-02-02 Novartis Ag Organic compounds
US7417147B2 (en) 2005-11-10 2008-08-26 Bodor Nicholas S Soft anticholinergic zwitterions
CA2627982C (en) 2005-11-10 2013-09-10 Nicholas S. Bodor Soft anticholinergic esters
WO2007068929A1 (en) * 2005-12-16 2007-06-21 Argenta Discovery Ltd. Cyclic amine derivatives and their uses
JP2009534463A (ja) * 2006-04-24 2009-09-24 アストラゼネカ・アクチエボラーグ 例えば慢性気管支閉塞、喘息および過活動膀胱の処置に有用な、ムスカリンｍ３受容体アンタゴニスト活性を有する環状アミノアルコールの新規アルキルエステル
TW200825084A (en) 2006-11-14 2008-06-16 Astrazeneca Ab New compounds 521
US20100112061A1 (en) * 2006-12-13 2010-05-06 William Baker Monophosphates as Mutual Prodrugs of Muscarinic Receptor Antagonists and Beta-Agonists for the Treatment of COPD And Chronic Bronchitis
RU2452728C2 (ru) * 2007-02-23 2012-06-10 Тереванс, Инк. Четвертичные аммониевые дифенилметилсоединения, применимые в качестве антагонистов мускариновых рецепторов
CA2697752C (en) * 2007-09-07 2016-01-26 Theravance, Inc. Guanidine-containing compounds useful as muscarinic receptor antagonists
JP2011506477A (ja) 2007-12-14 2011-03-03 セラヴァンス， インコーポレーテッド ムスカリン受容体拮抗薬として有用なアミジン含有化合物
AU2008356409B2 (en) 2008-05-13 2012-01-19 Astrazeneca Ab Quinuclidine derivatives as muscarinic M3 receptor antagonists
NZ595810A (en) * 2009-04-30 2013-05-31 Teijin Pharma Ltd Quaternary ammonium salt compound
US9156833B2 (en) 2012-07-16 2015-10-13 Barry University, Inc. Bitopic muscarinic agonists and antagonists and methods of synthesis and use thereof
PL3111978T3 (pl) 2015-07-03 2022-01-24 Novartis Ag Inhalator przystosowany do odczytu informacji przechowywanych w środkach przechowywania danych pojemnika
WO2021183639A1 (en) * 2020-03-11 2021-09-16 Nocion Therapeutics, Inc. Charged ion channel blockers and methods for use

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3240784A (en) * 1966-03-15 Esters of quaternary z-hydroxy methyl piperidinium compounds
US2746966A (en) * 1953-11-02 1956-05-22 Lakeside Lab Inc Esters of bis-(nu-substituted-3-hydroxypiperidinium) alkanes
GB833820A (en) * 1957-10-17 1960-04-27 Beecham Res Lab Improvements in or relating to the preparation of pyrrolidyl esters and quaternary compounds thereof
JPS6018661B2 (ja) * 1976-01-01 1985-05-11 太田製薬株式会社 １−（１，３−ジオキソラン−４−イルメチル）ピペリジノ−ル誘導体
JPS5427570A (en) * 1977-07-30 1979-03-01 Ota Pharma Stereoisomer of 44acyloxyy11 alkyll11*1*33dioxolanee44 ylmethyl* pideridinium salt derivative
JPS5679688A (en) * 1979-12-04 1981-06-30 Ota Seiyaku Kk 4-acyloxy-1- 1,3-dioxoran-2-ylmethyl piperidine derivative and its production
JPS5835177A (ja) 1981-08-26 1983-03-01 Dainippon Pharmaceut Co Ltd ２−環状アミノ−２−（１，２−ベンズイソキサゾ−ル−３−イル）酢酸エステル類並びにその酸付加塩類および第４級アンモニウム塩類
JPS58208270A (ja) * 1982-05-28 1983-12-03 Dainippon Pharmaceut Co Ltd α−環状アミノフエニル酢酸エステル類並びにその酸付加塩類及び第４級アンモニウム塩類
GB9023023D0 (en) 1990-10-23 1990-12-05 Barlow Richard B Pharmaceutical compositions
ATE269305T1 (de) 1995-04-28 2004-07-15 Banyu Pharma Co Ltd 1,4-disubstituierte piperidinderivate
DK1371645T3 (da) * 1996-11-11 2013-06-03 Meda Pharma Gmbh & Co Kg Anvendelse af (3S,2'R)-glycopyrronium som lægemiddel
AU2001271027B2 (en) * 2000-07-11 2005-07-07 Msd K.K. Ester derivatives
ES2206021B1 (es) * 2002-04-16 2005-08-01 Almirall Prodesfarma, S.A. Nuevos derivados de pirrolidinio.
US7417147B2 (en) * 2005-11-10 2008-08-26 Bodor Nicholas S Soft anticholinergic zwitterions

Also Published As

Publication number Publication date
CA2526991C (en) 2012-03-27
EP1638940A2 (en) 2006-03-29
PT1638940E (pt) 2010-11-08
AU2004251867A1 (en) 2005-01-06
PL1638940T3 (pl) 2011-02-28
EP1638940B1 (en) 2010-08-25
JP2008529965A (ja) 2008-08-07
WO2005000815A3 (en) 2005-04-14
BRPI0411738A (pt) 2006-08-08
ATE478845T1 (de) 2010-09-15
DE602004028821D1 (de) 2010-10-07
WO2005000815A2 (en) 2005-01-06
CA2526991A1 (en) 2005-01-06
MXPA05013823A (es) 2006-02-28
AU2004251867B2 (en) 2008-08-07
US20060287362A1 (en) 2006-12-21
PE20050231A1 (es) 2005-05-20
US7947730B2 (en) 2011-05-24
TW200526573A (en) 2005-08-16

Similar Documents

Publication Publication Date Title
AR044851A1 (es) Compuestos heterociclicos, antagonistas del receptor m3 muscarinico
AR044134A1 (es) Derivados de quinuclidina, metodo de preparacion y composiciones farmaceuticas.
CO5590957A2 (es) Amino-1,3,5-triazinas sustituidas en n con radicales biciclicos quirales, procedimiento para su preparacion, composiciones de las mismas y su uso como herbicidas y reguladores del crecimiento de las plantas
AR083367A1 (es) Compuestos de tipo quinazolinona como antagonistas de crth
PE20090630A1 (es) Derivados de indol 2-carboxi sustituidos y metodos para su utilizacion
CO6150158A2 (es) Piperidinas sustituidas que aumentan la actividad de p53 y su uso
AR058554A1 (es) Compuestos heterociclicos nitrogenados de 6 miembros sustituidos, metodos para su preparacion, composiciones farmaceuticas que los contienen y su uso en el tratamiento de enfermedades mediadas por mglur5.
MX9708802A (es) Amidas ciclicas fungicidas.
AR044402A1 (es) Compuestos heterociclicos y su uso como inmunodepresores. composiciones farmaceuticas que los contienen.
EA200400387A1 (ru) Азабициклические замещённые конденсированные гетероарильные соединения для лечения заболеваний
AR049388A1 (es) Heterociclos como inhibidores de aldosterona sintasa
AR057408A1 (es) Agonistas del receptor de niacina composiciones que contienen tales compuestos y procedimientos para tratamiento
AR023152A1 (es) Compuesto tienopirimidina, procedimiento para producirlo, composicion farmaceutica que lo comprende y uso de dicho compuesto para preparar dichacomposicion
ATE521606T1 (de) Quaternäre ammoniumsalze als m3-antagonisten
ATE497957T1 (de) Pyridinderivate als fungizide verbindungen
AR058885A1 (es) Compuestos de piperidina 3,5-sustituidos
PE20011294A1 (es) Composiciones farmaceuticas de agonistas/antagonistas de estrogeno y estatinas para tratar la osteoporosis y reducir el colesterol
AR026990A1 (es) Antagonistas de neurokinina selectivos
BR112015015812A2 (pt) derivados de pirimidina fundidos a pirido ou pirrolo como inibidores de autotaxina para tratamento de dor
AR041395A1 (es) Compuesto de piridina composicion farmaceutica que lo comprende y su uso para prepararla
MX9708807A (es) Amidas ciclicas fungicidas.
AR055171A1 (es) Derivados de carboxamida como antagonistas del receptor muscarinico
ATE541839T1 (de) Pyrrolidiniumderivate als m3-muskarinische rezeptoren
AR060903A1 (es) Derivados de 1,2,3,4-tetrahidro-quinolina como inhibidores de cetp
AR041786A1 (es) Derivados de azetidina como antagonistas del receptor ccr-3, un proceso para su preparacion, una composicion farmaceutica y el uso de dichos derivados para la elaboracion de un medicamento

Legal Events

Date Code Title Description
FA Abandonment or withdrawal